Literature DB >> 8653691

DPC4 gene in various tumor types.

M Schutte1, R H Hruban, L Hedrick, K R Cho, G M Nadasdy, C L Weinstein, G S Bova, W B Isaacs, P Cairns, H Nawroz, D Sidransky, R A Casero, P S Meltzer, S A Hahn, S E Kern.   

Abstract

We recently identified a novel tumor-suppressor gene, DPC4, at chromosome 18q21.1 and found that both alleles of DPC4 were inactivated in nearly one-half of the pancreatic carcinomas. Here, we analyzed 338 tumors, originating from 12 distinct anatomic sites, for alterations in the DPC4 gene. Sixty-four specimens were selected for the presence of the allelic loss of 18q and were further analyzed for DPC4 sequence alterations. An alteration of the DPC4 gene sequence was identified in one of eight breast carcinomas and one of eight ovarian carcinomas. These results indicate that whereas DPC4 inactivation is prevalent in pancreatic carcinoma (48%), it is distinctly uncommon (< 10%) in the other tumor types examined. The tissue restriction of alterations in DPC4, as in many other tumor-suppressor genes, emphasizes the complexity of rate-limiting checkpoints in human tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8653691

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  181 in total

1.  PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway.

Authors:  M Tan; Y Wang; K Guan; Y Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Structural basis for the functional difference between Smad2 and Smad3 in FAST-2 (forkhead activin signal transducer-2)-mediated transcription.

Authors:  R P Nagarajan; Y Chen
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

Review 3.  TGF-beta signaling in mammary gland development and tumorigenesis.

Authors:  L M Wakefield; E Piek; E P Böttinger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

4.  Loss of heterozygosity or intragenic mutation, which comes first?

Authors:  R E Wilentz; P Argani; R H Hruban
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

5.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 6.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

7.  Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma.

Authors:  Wen-Hua Xiao; Wei-Wen Liu
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

8.  Molecular structure of tail tendon fibers in TIEG1 knockout mice using synchrotron diffraction technology.

Authors:  Laurie Gumez; Sabine F Bensamoun; Jean Doucet; Oualid Haddad; John R Hawse; Malayannan Subramaniam; Thomas C Spelsberg; Chantal Pichon
Journal:  J Appl Physiol (1985)       Date:  2010-04-08

9.  Concordant repression and aberrant methylation of transforming growth factor-beta signaling pathway genes occurs early in gastric cardia adenocarcinoma.

Authors:  Wei Guo; Zhiming Dong; Yanli Guo; Gang Kuang; Zhibin Yang; Baoen Shan
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

10.  G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: phenotypes reversed by a tumorigenic mutation.

Authors:  J L Dai; R K Bansal; S E Kern
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.